ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
暂无分享,去创建一个
K. Stamatopoulos | D. Rossi | G. Gaidano | R. Rosenquist | T. Soussi | S. Stilgenbauer | Š. Pospíšilová | A. Kater | T. Zenz | D. Gonzalez | F. Davi | P. Ghia | C. Moreno | J. Malcikova | E. Tausch | P. Ghia | K. Stamatopoulos | J. Malcikova | E. Tausch | D. Rossi | L. A. Sutton | T. Soussi | T. Zenz | A. P. Kater | C. U. Niemann | D. Gonzalez | F. Davi | M. Gonzalez Diaz | C. Moreno | G. Gaidano | R. Rosenquist | S. Stilgenbauer | S. Pospisilova | A. Kater | C. Niemann | M. González Díaz | L. Sutton | Davide Rossi | Richard Rosenquist | T. Zenz | Carol Moreno | Frédéric Davi | Thierry Soussi | C. Niemann | David Gonzalez | M. G. Diaz
[1] Andrew J. Hill,et al. Analysis of protein-coding genetic variation in 60,706 humans , 2015, bioRxiv.
[2] J. Gribben,et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia , 2012, Leukemia.
[3] P. Taschner,et al. Recommendations for Analyzing and Reporting TP53 Gene Variants in the High‐Throughput Sequencing Era , 2014, Human mutation.
[4] J. Halgunset,et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. , 2005, The Journal of molecular diagnostics : JMD.
[5] R. Siebert,et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome , 2011, British journal of haematology.
[6] Raul Rabadan,et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.
[7] B. Dörken,et al. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis , 2005, BMC Cancer.
[8] T. Haferlach,et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype , 2009, Leukemia.
[9] T. Jensen,et al. Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes , 2015, Nature Reviews Molecular Cell Biology.
[10] Axel Benner,et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. , 2008, Blood.
[11] R. Ulrich,et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. , 2014, Blood.
[12] J. Delgado,et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. , 2006, Leukemia research.
[13] G. Gordon,et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. , 2016, The Lancet. Oncology.
[14] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[15] M. Cazzola,et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.
[16] D. Rossi,et al. The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness , 2009, Clinical Cancer Research.
[17] Š. Pospíšilová,et al. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods , 2015, Tumor Biology.
[18] K. Kinzler,et al. Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.
[19] Yoon-La Choi,et al. Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples , 2015, PloS one.
[20] Marc S. Williams,et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing , 2013, Genetics in Medicine.
[21] Raymond Dalgleish,et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.
[22] Martin Demko,et al. GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data , 2017, Bioinform..
[23] Viktor Ljungström,et al. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting , 2015, Haematologica.
[24] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[25] G. Morgan,et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Varley,et al. Characterization of germline TP53 splicing mutations and their genetic and functional analysis , 2001, Oncogene.
[27] Jian-yong Li,et al. TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia , 2014, Medical Oncology.
[28] Martin A. Nowak,et al. Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.
[29] G. Juliusson,et al. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. , 2011, Leukemia research.
[30] L. Donehower,et al. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. , 2017, Cancer research.
[31] Jay Shendure,et al. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation , 2013, Genome research.
[32] T. Soussi,et al. TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade , 2014, Human mutation.
[33] Thierry Soussi,et al. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes , 2016, International journal of cancer.
[34] J. Valcárcel,et al. Synonymous Mutations Frequently Act as Driver Mutations in Human Cancers , 2014, Cell.
[35] A. Jauch,et al. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia , 2013, British journal of haematology.
[36] A. McKenna,et al. Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.
[37] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Jeffrey A Jones,et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. , 2016, The Lancet. Oncology.
[39] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[40] H. Döhner,et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] James R. Eshleman,et al. Cytosine Deamination Is a Major Cause of Baseline Noise in Next-Generation Sequencing , 2014, Molecular Diagnosis & Therapy.
[42] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[43] Do-Hee Kim,et al. Abstract 1250: Curcumin inhibits migration and growth of human colon cancer cells through covalent modification of oncogenic SIRT1: Cysteine 67 as a potential binding site , 2017 .
[44] Š. Pospíšilová,et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia , 2014, Leukemia.
[45] M. Murphy,et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.
[46] T. Haferlach,et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases , 2017, Leukemia.
[47] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[48] Leslie Cope,et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. , 2014, American journal of clinical pathology.
[49] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.
[50] Š. Pospíšilová,et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. , 2009, Blood.
[51] Dmitriy Sonkin,et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data , 2016, Human mutation.
[52] A. López-Guillermo,et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.
[53] Thierry Soussi,et al. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors , 2012, Proceedings of the National Academy of Sciences.
[54] P. Taschner,et al. Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications , 2017, Human mutation.
[55] H. Döhner,et al. How little is too much? p53 inactivation: from laboratory cutoff to biological basis of chemotherapy resistance , 2008, Leukemia.
[56] F. Pontén,et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.
[57] Michael Hallek,et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. , 2009, Blood.